To explore the clinical effect of Guizhi Fuling capsule combined with mirena for treating women with adenomyosis, and to study its influence on their levels of CA125, Ang-2 and PGF2a. Methods: 90 women with adenomyosis were selected, and were divided into control group and observation group (45 cases in each group) according to the principle of random number method from February 2017 to October 2018. The women in the control group were treated with mirena for 6 months, and the women in the observation group were treated with Guizhi Fuling capsule combined with mirena for 6 months. The efficacy of women in the two groups was evaluated. The  changes of the levels of E2, FSH, LH, VEGF, HIF-1a, E-cadherin, Ang-2, CA125, CA199, HE4, MMP-7, PGF2a and APN of women in the two groups were measured before and after treatment. Results: After treatment, the total effective rate (93.3%) of women in the observation group was significant higher than that (77.8%) of women in the control group, and the levels of E2, E-Cadherin, and APN of women in the observation group levels were also significant higher, but the levels of  FSH, LH, VEGF, HIF-1, Ang-2, CA125, CA199, HE4, MMP-7, and PGF2a of women in the observation group were significant lower (all P＜0.05). The incidence of adverse reactions of women in the observation group during treatment was 6.7%, which had no significant different from that (8.9%) of women in the control group (P>0.05). Conclusion: Guizhi Fuling capsule combined with mirena for treating women with adenomyosis can not only significantly improve their clinical symptoms and signs, and the levels of related factors, and enhance the curative effect, but also does not increase adverse reactions, so it is safety and reliable.